Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety study of amifampridine phosphate in antibody-positive myasthenia gravis
2017-004777-14Phase 3Terminated
- Sponsor
- Catalyst Pharmaceuticals
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of amifampridine in myasthenia gravis (MG), sponsored by Catalyst Pharmaceuticals. Primary endpoint: Long-term safety and tolerability. Started Jan 2021; status: terminated.
02
Drugs
amifampridine
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2017-004777-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004777-14.